- Home
- KEN vs ARQT Comparison
KEN vs ARQT Comparison
Compare KEN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEN | ARQT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KEN | ARQT |
|---|---|---|
| Price | $69.37 | $29.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.83 |
| AVG Volume (30 Days) | 13.3K | ★ 1.8M |
| Earning Date | 12-03-2025 | 02-24-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | ★ 177.70 | N/A |
| EPS | ★ 8.96 | N/A |
| Revenue | ★ $803,304,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | N/A | $30.74 |
| P/E Ratio | $7.44 | ★ N/A |
| Revenue Growth | 8.15 | ★ 129.21 |
| 52 Week Low | $27.10 | $11.13 |
| 52 Week High | $67.69 | $31.77 |
Technical Indicators
Market Signals| Indicator | KEN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 73.97 | 58.76 |
| Support Level | $65.87 | $27.71 |
| Resistance Level | $67.57 | $30.26 |
| Average True Range (ATR) | 1.25 | 1.07 |
| MACD | 0.20 | -0.15 |
| Stochastic Oscillator | 93.59 | 90.42 |
Price Performance
Historical ComparisonAbout KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.